The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Elevated Expression of Wnt Antagonists Is a Common Event in Hepatoblastomas
Abstract
Hepatoblastomas are the most frequent malignant liver tumors of childhood. A high frequency of activating β-catenin mutations in hepatoblastomas indicates that the Wnt signaling pathway plays an important role in the development of this embryonic neoplasm. Stabilization of β-catenin leads to an increased formation of nuclear β-catenin-T-cell factor complexes and altered expression of Wnt-inducible target genes. In this study, we analyzed the mRNA expression levels of nine Wnt genes, including c-JUN, c-MYC, CYCLIN D1, FRA-1, NKD-1, ITF-2, MMP-7, uPAR, and β-TRCP, by competitive reverse transcription-PCR. We analyzed 23 hepatoblastoma biopsies for which matching liver tissue was available, 6 hepatoblastoma cell lines, and 3 human fetal liver samples. β-TRCP and NKD-1 were highly expressed in all hepatoblastoma samples, independent of the β-catenin mutational status, in comparison with their nontumorous counterparts. β-TRCP mRNA overexpression was associated with accumulation of intracytoplasmic and nuclear β-TrCP protein. In human liver tumor cells without β-catenin mutations, Nkd-1 inhibited the Wnt-3a-activated Tcf-responsive-luciferase reporter activity, whereas Nkd-1 in hepatoblastomas with β-catenin mutations had no antagonistic effect. Our data emphasize the inhibitory effect of β-TrCP and Nkd-1 on the Wnt signaling pathway in a manner analogous to Conductin (AXIN2) and Dkk-1, inhibitors shown previously to be up-regulated in hepatoblastomas. Our findings indicate that overexpression of the Wnt antagonists Nkd-1 and β-TrCP reveals an activation of the Wnt signaling pathway as a common event in hepatoblastomas. We propose that Nkd-1 and β-TrCP may be used as possible diagnostic markers for the activated Wnt signaling pathway in hepatoblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow
Bafico, A., Liu, G., Yaniv, A., Gazit, A., & Aaronson, S. A. (2001) · Nature Cell Biology · doi:10.1038/35083081 · Cited by 772
Cited by
NF‐κB and the link between inflammation and cancer
DiDonato, J. A., Mercurio, F., & Karin, M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01099.x · Cited by 1,482
Ubiquitin ligases: cell-cycle control and cancer
Nakayama, K. I., & Nakayama, K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1881 · Cited by 1,433
Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer
Frescas, D., & Pagano, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2396 · Cited by 890
Roles of F-box proteins in cancer
Wang, Z., Liu, P., Inuzuka, H., & Wei, W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3700 · Cited by 523
Cairo, S., Armengol, C., De Reyniès, A., Wei, Y., Thomas, E., Renard, C.-A., Goga, A., Balakrishnan, A., Semeraro, M., Gresh, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.002 · Cited by 509
Metadata
- Authors
- Koch, A., Waha, A., Hartmann, W., Hrychyk, A., Schüller, U., Waha, A., Wharton, K. A., Fuchs, S. Y., Schweinitz, D. V., & Pietsch, T.
- Venue
- Clinical Cancer Research
- Published
- 2005-06-15
- Volume
- 11
- Issue
- 12
- Pages
- 4295-4304
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2128987620
- Cited by
- 158
- References
- 2
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elevated Expression of Wnt Antagonists Is a Common Event in Hepatoblastomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1162
- The paper
- Koch, A., Waha, A., Hartmann, W., Hrychyk, A., Schüller, U., Waha, A., Wharton, K. A., Fuchs, S. Y., Schweinitz, D. V., & Pietsch, T. (2005). Elevated Expression of Wnt Antagonists Is a Common Event in Hepatoblastomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1162
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.